Skip to main content
Log in

Cancer and venous thromboembolism: prevention, treatment and survival

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Venous thromboembolism (VTE) occurs frequently in patients with cancer. It can be difficult to manage, sometimes delay cancer therapy and predicts for a worse prognosis. Hence, effective methods to prevent and treat VTE can reduce morbidity and mortality. Prophylaxis with anticoagulants is recommended for patients hospitalized for surgery or medical conditions, but is not routinely administered in the ambulatory setting. Traditional anticoagulation with a heparin followed by vitamin K antagonist therapy for cancer patients with acute VTE is associated with a high frequency of treatment failure and bleeding complications. Low molecular weight heparins (LMWHs) have simplified and improved the management of VTE, and recent studies suggest these agents may improve survival in patients with limited or early stage disease. This brief review will provide an update on the primary prevention and treatment of VTE and discuss the evidence for the survival advantage associated with LMWH use in patients with malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119(1):60–68

    Article  PubMed  Google Scholar 

  2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634

    Article  PubMed  CAS  Google Scholar 

  3. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464

    Article  PubMed  Google Scholar 

  4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850

    Article  PubMed  CAS  Google Scholar 

  5. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double- blind randomized multicentre trial with venographic assessment. Br J Surg 84(8):1099–1103

    Article  Google Scholar 

  6. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88(7):913–930

    Article  PubMed  CAS  Google Scholar 

  7. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92(10):1212–1220

    Article  PubMed  CAS  Google Scholar 

  8. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975–980

    Article  PubMed  CAS  Google Scholar 

  9. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4(11):2384–2390

    Article  PubMed  CAS  Google Scholar 

  10. Couban S, Goodyear M, Burnell M et al (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063–4069

    Article  PubMed  CAS  Google Scholar 

  11. Young AM, Begum G, Billingham LJ et al (2005) WARP—A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheter (CVCs). Proc ASCO #LBA8004

  12. Verso M, Agnelli G, Bertoglio S et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057–4062

    Article  PubMed  CAS  Google Scholar 

  13. Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):338S–400S

    Article  PubMed  CAS  Google Scholar 

  14. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 Suppl 1):I17–I21

    PubMed  Google Scholar 

  15. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488

    Article  PubMed  CAS  Google Scholar 

  16. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18(17):3078–3083

    PubMed  CAS  Google Scholar 

  17. Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153

    Article  PubMed  CAS  Google Scholar 

  18. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389–396

    Article  PubMed  CAS  Google Scholar 

  19. Hull RD, Pineo GF, Brant RF et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062–1072

    Article  PubMed  CAS  Google Scholar 

  20. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729–1735

    Article  PubMed  CAS  Google Scholar 

  21. Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR (1999) The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost 82(6):1600–1604

    PubMed  CAS  Google Scholar 

  22. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86(6):1586–1587

    PubMed  CAS  Google Scholar 

  23. Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135

    Article  PubMed  CAS  Google Scholar 

  24. Altinbas M, Coskun HS, Er O et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266–1271

    Article  PubMed  CAS  Google Scholar 

  25. Kakkar AK, Levine MN, Kadziola Z et al (2004) Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22(10):1944–1948

    Article  PubMed  CAS  Google Scholar 

  26. Sideras K, Schaefer PL, Okuno SH et al (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81(6):758–767

    Article  PubMed  CAS  Google Scholar 

  27. Cosgrove RH, Zacharski LR, Racine E, Andersen JC (2002) Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 28(1):79–87

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Agnes Yuet Ying Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, A.Y.Y. Cancer and venous thromboembolism: prevention, treatment and survival. J Thromb Thrombolysis 25, 33–36 (2008). https://doi.org/10.1007/s11239-007-0102-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0102-0

Keywords

Navigation